The Latest
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of LEQEMBI® (Lecanemab) For Early Alzheimer’s Disease
Canada’s drug regulator issues final positive recommendation to support public reimbursement of Leqembi® (lecanemab) for early Alzheimer’s disease, marking a key policy shift.
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit Of ORPATHYS® Plus TAGRISSO® In Treatment-Naïve Patients With MET-Overexpressing EGFR-mutated Lung Cancer In China
HUTCHMED announces significant progression-free survival gains in SANOVO trial combining ORPATHYS® and TAGRISSO® for MET-overexpressing EGFR-mutant lung cancer in China.